U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H12ClN3O3S
Molecular Weight 325.7722
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-06282999

SMILES

COc1ccc(cc1-c2cc(nc(=S)n2CC(=N)O)O)Cl

InChI

InChIKey=ICYNYWFGIDGBRD-UHFFFAOYSA-N
InChI=1S/C13H12ClN3O3S/c1-20-10-3-2-7(14)4-8(10)9-5-12(19)16-13(21)17(9)6-11(15)18/h2-5H,6H2,1H3,(H2,15,18)(H,16,19,21)

HIDE SMILES / InChI

Molecular Formula C13H12ClN3O3S
Molecular Weight 325.7722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

PF-06282999 is selective myeloperoxidase inactivator. PF-06282999 selectively activated human pregnane X receptor (PXR). Treatment of human HepaRG cells with PF-06282999 led to ∼14-fold induction in CYP3A4 mRNA and 5-fold increase in midazolam-1'-hydroxylase activity. [18F]-Fluoro-deoxy-glucose (FDG) was administered to Ldlr-/- mice with established atherosclerosis that had been treated with clinically relevant doses of PF-06282999, and reduced FDG signal was observed in animals treated with a dose of PF-06282999 that corresponded with reduced necrotic core area. PF-06282999 was developed for the treatment of acute coronary syndromes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.9 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.
2017 May
Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor.
2018 Jul
Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes.
2018 May
Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition.
2019

Sample Use Guides

5 and 15 mg/kg twice a day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 11:19:24 UTC 2021
Edited
by admin
on Sat Jun 26 11:19:24 UTC 2021
Record UNII
YO3O4Q2NC8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-06282999
Common Name English
1(2H)-PYRIMIDINEACETAMIDE, 6-(5-CHLORO-2-METHOXYPHENYL)-3,4-DIHYDRO-4-OXO-2-THIOXO-
Systematic Name English
2-(6-(5-CHLORO-2-METHOXYPHENYL)-4-OXO-2-THIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ACETAMIDE
Systematic Name English
Code System Code Type Description
PUBCHEM
71571306
Created by admin on Sat Jun 26 11:19:24 UTC 2021 , Edited by admin on Sat Jun 26 11:19:24 UTC 2021
PRIMARY
CAS
1435467-37-0
Created by admin on Sat Jun 26 11:19:24 UTC 2021 , Edited by admin on Sat Jun 26 11:19:24 UTC 2021
PRIMARY
FDA UNII
YO3O4Q2NC8
Created by admin on Sat Jun 26 11:19:24 UTC 2021 , Edited by admin on Sat Jun 26 11:19:24 UTC 2021
PRIMARY
DRUG BANK
DB11683
Created by admin on Sat Jun 26 11:19:24 UTC 2021 , Edited by admin on Sat Jun 26 11:19:24 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
within 24 hours postdose at the 200-mg dose
URINE
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
MODERATE INDUCER THROUGH MEDIATED BY THE PREGNANE X RECEPTOR
Related Record Type Details
METABOLITE -> PARENT
Metabolite was observed in liver microsomes and hepatocytes from preclinical species and humans.
TRACE
METABOLITE -> PARENT
Metabolite was observed in liver microsomes and hepatocytes from preclinical species and humans.
TRACE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC P.O. ADMINISTRATION

IN HEALTHY FASTED MALE SUBJECTS

SINGLE DOSE

Tmax PHARMACOKINETIC P.O. ADMINISTRATION

SINGLE DOSE

IN HEALTHY FASTED MALE SUBJECTS

Biological Half-life PHARMACOKINETIC SINGLE DOSE

P.O. ADMINISTRATION

IN HEALTHY FASTED MALE SUBJECTS

Biological Half-life PHARMACOKINETIC SINGLE DOSE

IN HEALTHY FASTED MALE SUBJECTS

P.O. ADMINISTRATION